US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Swiss specialty drugmaker Santhera Pharmaceuticals this afternoon announced a strategic change to its management team with the appointment of Dario Eklund as chief executive effective December 1, 2019. 4 November 2019
US therapeutic gene editing company Sangamo Therapeutics has appointed Sung Lee as executive vice president and chief financial officer, effective October 31, 2019. Mr Lee oversees finance, facilities and information technology functions for Sangamo and reports to the firm’s chief executive. 2 November 2019
USA-based biotech Ovid Therapeutics has made two senior leadership changes to further build the company’s capabilities as it approaches top-line results from the pivotal Phase III NEPTUNE trial for OV101 in Angelman syndrome, expected in mid-2020. 2 November 2019
Genmab, one of the world’s most notable biotech success stories of recent years, has announced that one of those who helped to drive its rapid growth is to retire. 1 November 2019
Shares of UK developer of inhaled therapeutics Vectura Group were up more than 1% at 84.07 pence, after it announced the appointment of Will Downie as chief executive and executive director of the company, effective November 7, 2019. 29 October 2019
Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27 years of service with the company, US pharma major Eli Lilly announced today. 23 October 2019
UK biotech start-up Achilles Therapeutics today announced the appointment of Beverley Carr as chief business officer, with effect from November 4, 2019. 21 October 2019
US biotech Gilead Sciences today announced that Andrew Dickinson has been appointed chief financial officer (CFO), effective November 1. 15 October 2019
The Switzerland-based company will be led in its next phase of growth and innovation by an experienced management team and board, with proven track records in building sustainable high-growth businesses in pharmaceutical and consumer industries. 9 October 2019
Handan He has left her role as global head of computational, biopharmaceutics and translational PK/PD at Novartis’ pharma unit to join Ascletis as chief scientific officer. 8 October 2019
Phathom Pharmaceuticals has announced that Terrie Curran will be appointed chief executive effective upon the closing of the acquisition of Celgene Corp by Bristol-Myers Squibb, 4 October 2019
Tridek-One, a privately-held French biotech specializing in the development of products for the treatment of immune and inflammatory disorders, has named three new members of its executive team. 2 October 2019
Louise Houson, who for three years has been the managing director (MD) for UK and Ireland at US pharma giant Merck & Co, has taken up a new USA-based role as global brand leader for HPV vaccines. 1 October 2019
Canada’s ImmunoPrecise Antibodies, a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of industry professional Dr Stefan Lang as chief business officer (CBO). 1 October 2019
France-headquartered biopharma firm Genfit has announced an executive reshuffle appointing Dr Dean Hum as president of Genfit Corp and Dr Suneil Hosmane as head of Global Diagnostics. 27 September 2019
The UK government-backed Cell and Gene Therapy Catapult (CGT Catapult) has announced that its chief executive, Keith Thompson, is to retire from April 2020. 26 September 2019
Hisamitsu Pharmaceutical subsidiary Noven Pharmaceuticals has appointed Naruhito Higo as chief executive, replacing Jeff Mihm, who has resigned. 24 September 2019